English
Home > Products > CAS NO 205448-65-3

China CAS NO 205448-65-3 Factory

In the past few years, our firm absorbed and digested highly developed technologies equally at home and abroad. Meanwhile, our business staffs a group of experts devoted on the growth of CAS NO 205448-65-3,205448-65-3,Lenvatinib intermediate,Lenvatinib advance intermediate,Methyl 7-Methoxy-4-oxo-1, We warmly welcome all intrigued clients to call us for additional details.
CAS NO 205448-65-3, We have a dedicated and aggressive sales team, and many branches, catering to our customers. We're looking for long-term business partnerships, and ensure our suppliers that they will undoubtedly benefit in both short and long run.

Related Products

Hot Products

  • N-METHYL-D-ALANINE

    N-METHYL-D-ALANINE

    Product Name:N-METHYL-D-ALANINE
    Molecular Formula:C4H9NO2
    Molecular Weight:103.12
    CAS Registry Number:29475-64-7
  • Nitazoxanide

    Nitazoxanide

    Product Name:Nitazoxanide
    Molecular Formula:C12H9N3O5S
    Molecular Weight;307.28
    CAS Registry Number;55981-09-4
  • 1-Bromopropane

    1-Bromopropane

    Product Name:1-Bromopropane
    Molecular Formula:C3H7Br
    Molecular Weight:122.99
    CAS Registry Number:106-94-5
  • Sarafloxacin hydrochloride

    Sarafloxacin hydrochloride

    Product Name:Sarafloxacin hydrochloride
    Molecular Formula:C20H18ClF2N3O3
    Molecular Weight;421.83
    CAS Registry Number;91296-87-6
  • Polyvinylpyrrolidone

    Polyvinylpyrrolidone

    Product Name:Polyvinylpyrrolidone
    Molecular Formula:CH4
    Molecular Weight:16.04246
    CAS Registry Number:9003-39-8
  • 1,2,3,4-Tetrahydro-1-naphthoic acid

    1,2,3,4-Tetrahydro-1-naphthoic acid

    Product Name:1,2,3,4-Tetrahydro-1-naphthoic acid
    Molecular Formula:C11H12O2
    Molecular Weight:176.21
    CAS Registry Number:1914-65-4
  • Related Blog
  • Reviews

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept